Publications by authors named "Rivera-Nieves J"

Background: Tumor necrosis factor (TNF) is a pleiotropic cytokine that plays a critical role in the pathogenesis of immune-mediated diseases including inflammatory bowel disease (IBD). The stability of its mRNA transcript, determined in part by destabilizing sequences in its AAUU repeats (ARE) gene region, is an important regulator of its tissue and systemic levels. A deletion in the ARE region of the gene resulted in IBD and arthritis in mice and pigs, supporting a critical role for the cytokine in human IBD and several human arthritides.

View Article and Find Full Text PDF
Article Synopsis
  • Inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis are chronic conditions affecting the intestines, leading to new treatment options through immunotherapies.
  • Recently developed S1P modulators, such as ozanimod and etrasimod, work by sequestering T cells in lymphoid tissues, reducing their migration to inflamed gut areas, which helps in controlling IBD symptoms.
  • This review highlights the role of the S1P/S1PR signaling pathway in IBD, evaluates the effectiveness and safety of current S1P modulators, and explores future treatment possibilities targeting this pathway.
View Article and Find Full Text PDF

Eighty percent of antibody secreting cells (ASCs) are found in the intestine, where they produce grams of immunoglobulin (Ig) A daily. immunoglobulin A is actively transcytosed into the lumen, where it plays a critical role in modulating the gut microbiota. Although loss of immune tolerance to bacterial antigens is the likely trigger of the dysregulated immune response that characterizes inflammatory bowel disease (IBD), little effort has been placed on understanding the interface between B cells, IgA, and the microbiota during initiation or progression of disease.

View Article and Find Full Text PDF

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn disease (CD), has emerged as a global disease with an increasing incidence in developing and newly industrialized regions such as South America. This global rise offers the opportunity to explore the differences and similarities in disease presentation and outcomes across different genetic backgrounds and geographic locations. Our study includes 265 IBD patients.

View Article and Find Full Text PDF

Lymphocytes within the intestinal epithelial layer (IEL) in mammals have unique composition compared with their counterparts in the lamina propria. Little is known about the role of some of the key colonic IEL subsets, such as TCRαβCD8 T cells, in inflammation. We have recently described liver-enriched innate-like TCRαβCD8αα regulatory T cells, partly controlled by the non-classical MHC molecule, Qa-1, that upon adoptive transfer protect from T cell-induced colitis.

View Article and Find Full Text PDF

Over the last several years, many advances have been made in understanding the role of bacteria in the pathogenesis of gastrointestinal cancers. Beginning with being recognized as the first bacterial carcinogen and the causative agent of most gastric cancers, more recent studies have examined the role of enteric microbes in colorectal cancer. In the digestive tract, these communities are numerous and have a complex interrelationship with local immune/inflammatory responses that impact the health of the host.

View Article and Find Full Text PDF

T and B cells employ integrin α4β7 to migrate to intestine under homeostatic conditions. Whether those cells differentially rely on α4β7 for homing during inflammatory conditions has not been fully examined. This may have implications for our understanding of the mode of action of anti-integrin therapies in inflammatory bowel disease (IBD).

View Article and Find Full Text PDF

Efficient IgA transcytosis is critical for the maintenance of a homeostatic microbiota. In the canonical model, locally-secreted dimeric (d)IgA reaches the polymeric immunoglobulin receptor (pIgR) on intestinal epithelium via simple diffusion. A role for integrin αE(CD103)β7 during transcytosis has not been described, nor its expression by intestinal B cell lineage cells.

View Article and Find Full Text PDF
Article Synopsis
  • Sphingosine-1-phosphate (S1P) is a lipid metabolite that interacts with 5 G-protein-coupled receptors to regulate lymphocyte trafficking, impacting immune responses and diseases.
  • An S1P gradient (low in tissues, high in blood) is crucial for lymphocyte movement; modulating this pathway can therapeutically affect conditions like multiple sclerosis and other immune-mediated diseases.
  • While some S1PR modulators show promise in treating autoimmune diseases and COVID-19, they come with potential side effects such as leukopenia and elevated transaminases, requiring careful administration.
View Article and Find Full Text PDF

Background: Vedolizumab, an α4β7 integrin antagonist, is an effective therapy for Crohn's disease (CD). Biomarkers are needed to guide therapy and predict outcomes. This study evaluated biomarker concentrations and outcomes in patients with CD undergoing vedolizumab treatment.

View Article and Find Full Text PDF

Background And Aims: Intestinal biopsy sampling during IBD trials represents a valuable adjunct strategy for understanding drug responses at the tissue level. Given the length and distinctive embryonic origins of the proximal and distal colon, we investigated whether inherent regional differences of immune cell composition could introduce confounders when sampling different disease stages, or pre/post drug administration. Here, we capitalise on novel mass cytometry technology to perform deep immunophenotyping of distinct healthy colonic segments, using the limited numbers of biopsies that can be harvested from patients.

View Article and Find Full Text PDF
Article Synopsis
  • - The study explores the role of sphingosine-1-phosphate lyase (SPL) in the intestine, particularly its impact on S1P levels and lymphocyte behavior in both healthy and inflamed conditions like inflammatory bowel disease (IBD).
  • - Researchers conducted experiments using specific SPL inhibitors on mice with Crohn's-like chronic ileitis to observe changes in lymphocyte circulation, inflammation levels, and tissue S1P concentrations.
  • - Results showed that SPL is widely expressed in the gut, primarily in intestinal epithelial cells, and its inhibition significantly raised local S1P levels, suggesting a potential therapeutic avenue for managing gut inflammation without common side effects linked to S1P receptor targeting.
View Article and Find Full Text PDF
Article Synopsis
  • Integrin α4β7 is crucial for lymphocyte movement to the gut, impacting conditions like inflammatory bowel disease (IBD).
  • Loss of β7 integrin function in mouse models led to worsened colitis by impairing Treg cell homing to the gut, although their suppressive abilities remained intact.
  • These findings indicate that IBD patients with diminished Treg activity or interleukin 10 may not respond well to therapies targeting α4β7.
View Article and Find Full Text PDF

Crohn's disease (CD) is an inflammatory bowel disease that can involve any region of the gastrointestinal tract. First described in 1932 as terminal ileitis or regional enteritis, it predominately involves the ileum with or without colonic involvement. Isolated colonic CD was first described in 1960 and since then the phenotypic classification of CD has evolved to stratify patients into isolated ileal, ileocolonic, or isolated colonic involvement.

View Article and Find Full Text PDF
Article Synopsis
  • Inflammatory Bowel Diseases (IBDs) are chronic conditions affecting the gastrointestinal tract, with treatments like biological therapies showing varied effectiveness due to their complexity and immunogenicity.
  • Recent advancements in understanding IBD mechanisms have led to new treatment options, particularly focusing on small molecules (SMs) which are easier to administer and less likely to provoke immune responses.
  • Janus Kinase (JAK) inhibitors and Sphingosine-1-Phosphate Receptor (S1PR) agonists are emerging as promising SM treatments for IBD, targeting specific pathways that contribute to the disease's pathology.
View Article and Find Full Text PDF

Background: Vedolizumab inhibits α4β7-mediated lymphocyte trafficking and is effective in ulcerative colitis (UC). This study evaluated drug and biomarker concentrations and patient outcomes during vedolizumab treatment in UC.

Methods: Prospectively scored maintenance clinical (26.

View Article and Find Full Text PDF

The liver-gut immune axis is enriched in several innate immune cells, including innate-like unconventional and adaptive T cells that are thought to be involved in the maintenance of tolerance to gut-derived antigens and, at the same time, enable effective immunity against microbes. Two subsets of lipid-reactive CD1d-restricted natural killer T (NKT) cells, invariant NKT (iNKT) and type II NKT cells present in both mice and humans. NKT cells play an important role in regulation of inflammation in the liver and gut due to their innate-like properties of rapid secretion of a myriad of pro-inflammatory and anti-inflammatory cytokines and their ability to influence other innate cells as well as adaptive T and B cells.

View Article and Find Full Text PDF
Article Synopsis
  • After 20 years of focusing on pro-inflammatory cytokines for IBD treatment, new strategies targeting leukocyte traffic have emerged as effective alternatives.
  • Two drugs, natalizumab and vedolizumab, are already approved, with more in phase 3 trials targeting various molecules involved in immune cell movement.
  • Future treatments may include new small molecules, allosteric inhibitors, and nanovectors that enhance the modulation of inflammatory cell trafficking in IBD.
View Article and Find Full Text PDF